US equities |
GOOGL $283.82 ▼-12.64% GOOG $282.32 ▼-12.29% MU $934.27 ▼-4.98% MSFT $530.14 ▼-0.16% AMZN $243.79 ▼-4.25% META $624.52 ▲+1.96% NVDA $213.66 ▼-0.80% AAPL $348.91 ▲+1.48%
FinancialContent

Articles published by CARRICK THERAPEUTICS LIMITED

News headline image
Carrick Therapeutics Announces Positive Results from Phase 2 Randomized Trial of Samuraciclib in Combination with Fulvestrant in Patients with Hormone Receptor Positive, HER2 Negative Advanced Breast Cancer
From CARRICK THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Carrick Therapeutics Announces New Clinical Data Supporting Biomarker-driven Patient Selection for Samuraciclib (CDK7i) in Combination with SERDs in Hormone Receptor Positive Advanced Breast Cancer
From CARRICK THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Carrick Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT7439 (CDK12/13 Inhibitor)
From CARRICK THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Carrick Therapeutics Establishes New Headquarters in Boston, Massachusetts
From CARRICK THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Carrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in Combination with Vepdegestrant in Patients with Advanced Breast Cancer
From CARRICK THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers ARVN PFE
News headline image
Carrick Therapeutics Announces First Patient Dosed in Phase 2b Clinical Trial of Samuraciclib in Combination with Fulvestrant in Patients with Advanced HR+, HER2- Breast Cancer
From CARRICK THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Carrick Therapeutics Announces U.S. FDA Clearance of IND for CT7439, a First-In-Class Inhibitor of CDK12/13
From CARRICK THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Carrick Therapeutics Announces Clinical Trial Collaboration with Arvinas and Pfizer to Evaluate Samuraciclib and Vepdegestrant Combination
From CARRICK THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers ARVN PFE
News headline image
Carrick Therapeutics Closes Series C Financing
From CARRICK THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Carrick Therapeutics Announces $35 Million Investment from Pfizer
From CARRICK THERAPEUTICS LIMITED
Via GlobeNewswire